Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 42, Issue 3

Issues

Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer

Barbara Mroczko / Maciej Szmitkowski / Urszula Wereszczynska-Siemiatkowska / Grazyna GrazynaJurkowska
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2004.047

Abstract

Stem cell factor (SCF)and macrophage-colony stimulating factor (M-CSF)have assumed an increasing importance in cancer biology. In the present study we investigated the serum levels of these cytokines in pancreatic cancer patients in relation to controls and to patients with benign lesions of the pancreas (chronic pancreatitis group). The classical tumor markers, such as carcinoembryonic antigen (CEA)and carbohydrate antigen 19–9 (CA 19–9)were also tested. We compared the serum levels of cytokines with tumor stage. We also defined the receiver-operating characteristics (ROC)curve for cytokines and classical tumor markers. The cytokines were measured in 47 patients with pancreatic cancer, in 27 patients with chronic pancreatitis and in 35 healthy subjects. SCF and M-CSF were determined using enzyme-linked immunosorbent assay (ELISA). CEA and CA 19–9 were measured by microparticle enzyme immunoassay. There were significant differences in the levels of circulating SCF, M-CSF, CEA and CA 19–9 in the pancreatic cancer patients compared to the control group, but only the serum levels of M-CSF, CEA and CA 19–9 were significantly higher in pancreatic cancer patients compared to the pancreatitis group. The levels of cytokines and tumor markers were higher in patients with a more advanced tumor stage. The M-CSF serum levels correlated positively with the tested tumor markers. The M-CSF area under the ROC curve was higher than the SCF area. These results suggest that M-CSF is a better candidate for a pancreatic cancer tumor marker than SCF.

About the article

Published Online: 2005-06-01

Published in Print: 2004-03-09


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 42, Issue 3, Pages 256–260, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.047.

Export Citation

Copyright © 2004 by Walter de Gruyter GmbH & Co. KG.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Mads Grønborg, Troels Zakarias Kristiansen, Akiko Iwahori, Rubens Chang, Raghunath Reddy, Norihiro Sato, Henrik Molina, Ole Nørregaard Jensen, Ralph H. Hruban, Michael G. Goggins, Anirban Maitra, and Akhilesh Pandey
Molecular & Cellular Proteomics, 2006, Volume 5, Number 1, Page 157
[2]
Yandiswa Yolanda Yako, Deirdré Kruger, Martin Smith, Martin Brand, and Francisco X. Real
PLOS ONE, 2016, Volume 11, Number 5, Page e0154016
[3]
Robert J. Snyder, John Lantis, Robert S. Kirsner, Vivek Shah, Michael Molyneaux, and Marissa J. Carter
Wound Repair and Regeneration, 2016, Volume 24, Number 4, Page 613
[4]
Xiaolong Meng and Neil H. Riordan
Medical Hypotheses, 2006, Volume 66, Number 3, Page 486
[5]
Sławomir Ławicki, Maciej Szmitkowski, and Marek Wojtukiewicz
Clinica Chimica Acta, 2006, Volume 371, Number 1-2, Page 112
[6]
Magdalena Groblewska, Barbara Mroczko, Urszula Wereszczyńska-Siemiątkowska, Piotr Myśliwiec, Bogusław Kędra, and Maciej Szmitkowski
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 1
[7]
Marta Łukaszewicz-Zając, Barbara Mroczko, Mirosław Kozłowski, Jacek Nikliński, Jerzy Laudański, and Maciej Szmitkowski
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 10
[8]
Barbara Mroczko, Maciej Szmitkowski, Urszula Wereszczyńska-Siemiątkowska, and Grażyna Jurkowska
Clinical Chemistry and Laboratory Medicine (CCLM), 2005, Volume 43, Number 2
[9]
Barbara Mroczko, Marta Lukaszewicz-Zajac, Urszula Wereszczynska-Siemiatkowska, Magdalena Groblewska, Mariusz Gryko, Boguslaw Kedra, Grazyna Jurkowska, and Maciej Szmitkowski
Pancreas, 2009, Volume 38, Number 6, Page 613
[10]
Mark Aspinall-O'Dea and Eithne Costello
PROTEOMICS – CLINICAL APPLICATIONS, 2007, Volume 1, Number 9, Page 1066
[12]
Barbara Mroczko, Maciej Szmitkowski, Urszula WereszczyńSka-Siemiątkowska, and Bogna Okulczyk
Digestive Diseases and Sciences, 2005, Volume 50, Number 6, Page 1019

Comments (0)

Please log in or register to comment.
Log in